158 related articles for article (PubMed ID: 34711320)
1. A highly specific aptamer probe targeting PD-L1 in tumor tissue sections: Mutation favors specificity.
Ren X; Li J; Wu X; Zhao J; Yang Q; Lou X
Anal Chim Acta; 2021 Nov; 1185():339066. PubMed ID: 34711320
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging.
Li J; Ren X; Zhao J; Lou X
Analyst; 2021 May; 146(9):2910-2918. PubMed ID: 33724284
[TBL] [Abstract][Full Text] [Related]
3. Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1.
Li ZF; Chen C; Zeng JY; Wang S; Han SQ; Zhang YQ; Qiu DD; Guo HX
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):3997-4004. PubMed ID: 34156677
[TBL] [Abstract][Full Text] [Related]
4. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
5. Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach.
Khedri M; Abnous K; Rafatpanah H; Nabavinia MS; Taghdisi SM; Ramezani M
Immunol Invest; 2020 Jul; 49(5):535-554. PubMed ID: 32429721
[TBL] [Abstract][Full Text] [Related]
6. An improved SELEX technique for selection of DNA aptamers binding to M-type 11 of Streptococcus pyogenes.
Hamula CL; Peng H; Wang Z; Tyrrell GJ; Li XF; Le XC
Methods; 2016 Mar; 97():51-7. PubMed ID: 26678795
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
8. Speeding up in Vitro Discovery of Structure-Switching Aptamers via Magnetic Cross-Linking Precipitation.
Qiao N; Li J; Wu X; Diao D; Zhao J; Li J; Ren X; Ding X; Shangguan D; Lou X
Anal Chem; 2019 Nov; 91(21):13383-13389. PubMed ID: 31580650
[TBL] [Abstract][Full Text] [Related]
9. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
[TBL] [Abstract][Full Text] [Related]
10. Gold nanoparticle-streptavidin conjugates for rapid and efficient screening of aptamer function in lateral flow sensors using novel CD4-binding aptamers identified through Crossover-SELEX.
Fellows T; Ho L; Flanagan S; Fogel R; Ojo D; Limson J
Analyst; 2020 Aug; 145(15):5180-5193. PubMed ID: 32567629
[TBL] [Abstract][Full Text] [Related]
11. An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer.
Liu M; Wang Z; Tan T; Chen Z; Mou X; Yu X; Deng Y; Lu G; He N
Theranostics; 2018; 8(20):5772-5783. PubMed ID: 30555580
[TBL] [Abstract][Full Text] [Related]
12. Aptamers Targeting the PD-1/PD-L1 Axis: A Perspective.
Bertrand P
J Med Chem; 2023 Aug; 66(16):10878-10888. PubMed ID: 37561598
[TBL] [Abstract][Full Text] [Related]
13. Precise selection of aptamers targeting PD-L1 positive small extracellular vesicles on magnetic chips.
Dong HY; Xie QH; Pang DW; Chen G; Zhang ZL
Chem Commun (Camb); 2021 Apr; 57(29):3555-3558. PubMed ID: 33704314
[TBL] [Abstract][Full Text] [Related]
14. Developing Aptamers by Cell-Based SELEX.
Catuogno S; Esposito CL; de Franciscis V
Methods Mol Biol; 2016; 1380():33-46. PubMed ID: 26552814
[TBL] [Abstract][Full Text] [Related]
15. Investigating the Influences of Random-Region Length on Aptamer Selection Efficiency Based on Capillary Electrophoresis-SELEX and High-Throughput Sequencing.
Zhu C; Li L; Yang G; Qu F
Anal Chem; 2021 Dec; 93(51):17030-17035. PubMed ID: 34908408
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
18. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
19. Comparison of whole-cell SELEX methods for the identification of Staphylococcus aureus-specific DNA aptamers.
Moon J; Kim G; Park SB; Lim J; Mo C
Sensors (Basel); 2015 Apr; 15(4):8884-97. PubMed ID: 25884791
[TBL] [Abstract][Full Text] [Related]
20. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamer developed by Cell-SELEX.
Yuan B; Jiang X; Chen Y; Guo Q; Wang K; Meng X; Huang Z; Wen X
Talanta; 2017 Aug; 170():56-62. PubMed ID: 28501211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
